GT BIOPHARMA, INC. Adjustments to Additional Paid in Capital, Warrant Issued
GT BIOPHARMA, INC. (GTBP) reported Adjustments to Additional Paid in Capital, Warrant Issued of $164.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-08-14
- GT BIOPHARMA, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2026-06-30 was $164.00K.
- GT BIOPHARMA, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2023-12-31 was $0.00.
- GT BIOPHARMA, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2023-09-30 was $0.00.
- GT BIOPHARMA, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2023-06-30 was $0.00.
- GT BIOPHARMA, INC. adjustments to additional paid in capital, warrant issued for fiscal 2023 was $5.83M.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|---|
| 2026-06-30 | $164.00K 10-Q · filed 2026-08-14 | $164.00K 10-Q · filed 2026-08-14 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $0.00 derived: sum of 2 quarters · filed 2025-02-21 | $0.00 derived: sum of 3 quarters · filed 2025-02-21 | $5.83M 10-K · filed 2025-02-21 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $5.83M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $5.83M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $5.83M 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |